病毒性肺炎患者静脉-静脉体外膜氧合支持中凝血功能障碍与血栓、出血及死亡率的相关性
该研究在50例因病毒性肺炎接受静脉-静脉体外膜氧合(VV-ECMO)的患者中,于插管时、VV-ECMO期间(每5天)、拔管后1小时和24小时检测凝血因子、血管性血友病因子谱和凝血酶生成。结果显示,插管前凝血酶生成降低(<500 nM·min)和VWF:RCo/VWF:Ag比值降低可预测大出血,大出血与死亡率增加相关(3.6倍),而血栓形成无影响。
要点
- 插管前凝血酶生成<500 nM·min和VWF:RCo/VWF:Ag比值<0.7预测大出血。
- 大出血与死亡率增加相关(3.6倍),血栓形成对死亡率无影响。
- VV-ECMO启动后24小时内凝血因子水平显著下降,第5天恢复正常。
核心结论
- 插管前凝血酶生成降低(<500 nM·min)、VWF:RCo/VWF:Ag比值降低和组织因子途径抑制物α水平升高对大出血有显著影响,而大出血与死亡率增加相关。
研究设计与样本
- 研究纳入50例因病毒性肺炎导致呼吸衰竭并接受VV-ECMO支持的患者,于2018年8月至2020年1月期间,在插管时、VV-ECMO期间(每5天)、拔管后1小时和24小时测量凝血因子(FII、FV、FVII、FVIII、FIX、FX、FXI、FXII)、血管性血友病因子谱和凝血酶生成。
主要发现
- 患者中位年龄47岁(范围18-68),56%为男性,VV-ECMO中位持续时间9天(范围3-41)。
- 启动VV-ECMO后24小时内颅内出血和缺血性卒中分别检出10%和4%;180天死亡率为10%;58%发生血栓形成,28%发生大出血(其中43%为颅内出血)。
- 启动VV-ECMO后24小时内凝血因子水平显著下降,但第5天恢复正常;凝血酶生成在整个VV-ECMO期间显著降低,拔管时达最低点。
- 组织因子途径抑制物α水平在整个VV-ECMO期间升高,并与凝血酶生成降低(r=-0.54,P<.001)和延迟(r=0.6,P<.001)相关;VWF:RCo/VWF:Ag比值在启动后24小时及VV-ECMO期间较插管前显著降低。
- 多变量分析中,高龄、血小板减少、肌酐水平升高和插管时凝血酶生成降低与死亡率相关;插管前VWF:RCo/VWF:Ag比值<0.7和低凝血酶生成(<500 nM·min)预测大出血,而纤维蛋白原水平升高和凝血酶生成增加增加血栓风险;大出血与死亡率增加相关(3.6倍),血栓形成无影响。
关键数值与推荐
- 插管前凝血酶生成<500 nM·min和VWF:RCo/VWF:Ag比值<0.7预测大出血。
- 大出血与死亡率增加相关(3.6倍)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding and thrombosis remain leading causes of morbidity and mortality in patients supported by extracorporeal membrane oxygenation (ECMO). OBJECTIVES: To assess hemostatic changes during veno-venous (VV)-ECMO support after respiratory failure due to viral pneumonia and their association with major bleeding, thrombosis, and mortality. METHODS: Coagulation factors (factors [F]II, FV, FVII, FVIII, FIX, FX, FXI, FXII), von Willebrand profile, and thrombin generation (TG) were measured at cannulation, during VV-ECMO (every fifth day), 1 hour, and 24 hours after decannulation in 50 patients (August 2018-January 2020). RESULTS: Median age was 47 (18-68) years, 56% were men, and median VV-ECMO duration was 9 (3-41) days. Intracranial hemorrhage and ischemic stroke were detected in 10% and 4%, respectively, within 24 hours of initiating VV-ECMO. The 180-day mortality was 10%; 58% developed thrombosis and 28% major bleeding (43% were intracranial hemorrhage). Coagulation factor levels fell significantly within 24 hours of initiating VV-ECMO but returned to normal by day 5. TG decreased significantly throughout VV-ECMO, with nadir at decannulation. Tissue factor pathway inhibitor alpha level increased throughout VV-ECMO and correlated with reduced (r = -0.54, P < .001) and delayed (r = 0.6, P < .001) TG. The von Willebrand factor (VWF) Ristocetin cofactor activity (VWF:RCo)/VWF antigen (VWF:Ag) ratio was significantly reduced by 24 hours of initiation and during VV-ECMO compared to precannulation. In multivariate analyses, older age, thrombocytopenia, increased creatinine level, and reduced TG at cannulation were associated with mortality. VWF:RCo/VWF:Ag ratio <0.7 and low TG (< 500 nM·min) at precannulation predicted major bleeding while raised fibrinogen level and TG increased thrombotic risk. Major bleeding was associated with increased mortality (3.6-fold) while thrombosis had no impact. CONCLUSION: Precannulation reduced TG (<500 nM·min), reduced VWF:RCo/VWF:Ag ratio and increased tissue factor pathway inhibitor alpha levels had significant impacts on major bleeding, which was associated with increased mortality.
引用
- Arachchillage DJ, Gaspar M, Gierula M, et al. Association of coagulation dysfunction with thrombosis, bleeding, and mortality in patients supported by veno-venous extracorporeal membrane oxygenation for viral pneumonia. J Thromb Haemost. 2025. PMID: 40876759. doi:10.1016/j.jtha.2025.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。